南微医学科技股份有限公司持股5%以上股东减持股份结果公告

Group 1 - Major shareholder Shenzhen Zhongke Investment Co., Ltd. held 41,752,818 shares, accounting for 22.2270% of the total share capital before the reduction plan [1][2] - The reduction plan aimed to sell up to 3,756,948 shares, representing 2% of the total share capital, but only 62,000 shares were sold by the deadline [2][4] - The reduction was conducted in compliance with relevant laws and regulations, and the actual reduction met the planned minimum [4] Group 2 - The company will hold a Q3 performance briefing on December 16, 2025, from 10:00 to 11:00 AM, via the Shanghai Stock Exchange Roadshow Center [6][8] - Investors can submit questions from December 9 to December 15, 2025, for discussion during the briefing [11][12] - Key personnel attending the briefing include the CEO and other senior executives [8][10] Group 3 - The National Intellectual Property Administration upheld the validity of the company's patent for a hemostatic clip, which was challenged by Beijing Zhongke Shengkang Technology Co., Ltd. [15][17] - The invalidation request did not negatively impact the company's operations or financial results [16][19] - The company is currently involved in litigation against Zhongke Shengkang for patent infringement, with a previous ruling in its favor [18]